A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With Nivolumab in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs ASP-1948 (Primary) ; Nivolumab
- Indications Advanced breast cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma Global Development
- 23 May 2019 Planned number of patients changed from 254 to 474.
- 05 Jul 2018 Status changed from not yet recruiting to recruiting.
- 28 Jun 2018 New trial record